Objective-Mitogen-activated protein kinase pathways play an important role in neointima formation secondary to vascular injury, in part by promoting proliferation of vascular smooth muscle cells (VSMC). Mixed-lineage kinase 3 (MLK3) is a mitogen-activated protein kinase kinase kinase that activates multiple mitogen-activated protein kinase pathways and has been implicated in regulating proliferation in several cell types. However, the role of MLK3 in VSMC proliferation and neointima formation is unknown. The aim of this study was to determine the function of MLK3 in the development of neointimal hyperplasia and to elucidate the underlying mechanisms. Approach and Results-Neointima formation was analyzed after endothelial denudation of carotid arteries from wild-type and MLK3-deficient mice. MLK3 deficiency promoted injury-induced neointima formation and increased proliferation of primary VSMC derived from aortas isolated from MLK3-deficient mice compared with wild-type mice. Furthermore, MLK3 deficiency increased the activation of p63Rho guanine nucleotide exchange factor, RhoA, and Rho kinase in VSMC, a pathway known to promote neointimal hyperplasia, and reconstitution of MLK3 expression attenuated Rho kinase activation. Furthermore, cJun NH 2 -terminal kinase activation was decreased in MLK3-deficient VSMC, and proliferation of wild-type but not MLK3 knockout cells treated with a cJun NH 2 -terminal kinase inhibitor was attenuated. Conclusions-We demonstrate that MLK3 limits RhoA activation and injury-induced neointima formation by binding to and inhibiting the activation of p63Rho guanine nucleotide exchange factor, a RhoA activator. In MLK3-deficient cells, activation of p63Rho guanine nucleotide exchange factor proceeds in an unchecked manner, leading to a net increase in RhoA pathway activation. Reconstitution of MLK3 expression restores MLK3/p63Rho guanine nucleotide exchange factor interaction, which is attenuated by feedback from activated cJun NH 2 -terminal kinase. Furthermore, ectopic overexpression of kinase-inactive MLK3 is able to rescue mitogen-induced activation of ERK in cells that have been depleted of endogenous MLK3, 15 and MLK3 missense mutations have been identified in gastrointestinal tumors that probably affect MLK3 scaffold properties but not its kinase activity. 25 In addition, MLK3 has been shown to limit RhoA activation by binding p63Rho guanine nucleotide exchange factor (GEF), independently of its catalytic activity. 26 Interestingly, p63RhoGEF has been identified as a key mediator of angiotensin II-dependent RhoA activation in VSMC.
V ascular response to mechanical injury comprises 2 main processes: neointimal hyperplasia and vessel remodeling. 1 In particular, release of growth factors, infiltration of inflammatory cells, and vascular smooth muscle cell (VSMC) proliferation are involved in neointimal hyperplasia. 1 Proliferation in many cell types is driven by mitogenactivated protein kinase (MAPK) activation. The 3 major subfamilies of MAPKs, that is, extracellular signal-regulated kinase (ERK), c-Jun N-terminal Kinase (JNK), and p38MAPK, are activated in response to stimuli such as cytokines and growth factors, [2] [3] [4] and studies using both genetic models [5] [6] [7] and pharmacological inhibitors of MAPKs [8] [9] [10] [11] showed significant inhibition of neointimal hyperplasia after injury, indicating that MAPKs promote neointima formation.
MAPKs are regulated by a 3-tiered kinase cascade in which the MAPK is phosphorylated and activated by an MAP kinase kinase, which in turn is phosphorylated and activated by an MAP kinase kinase kinase. 2 Mixed-lineage kinase (MLK) 3 is a ubiquitously expressed member of MLKs (MLK1-4), a family of MAP kinase kinase kinases that regulates multiple MAPK pathways. 12 MLK3 function is modulated by interaction with the Rho family GTPases Cdc42 and Rac1, 13, 14 and MLK3 has been implicated in regulating proliferation, migration, and differentiation in several cell types. [15] [16] [17] Analysis of MLK3-deficient mice (Mlk3 −/− ) has demonstrated that MLK3 contributes to tumor necrosis factor-stimulated JNK activation in mouse embryonic fibroblasts, promotes diet-induced JNK activation in liver and adipose tissue, [18] [19] [20] [21] [22] and regulates bone development, 23 but its role in VSMC function and vessel wall integrity has not been studied. In addition to its role as upstream activator of MAPKs, there is emerging evidence for MAP kinase kinase kinase-independent functions of MLK3 that do not require MLK3 catalytic activity, indicating that MLK3 may also act as scaffold for protein complexes. Thus, it has been demonstrated that MLK3 is activated during G2/M phase and promotes
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July 2014 microtubule instability, independently of JNK activation. 24 Furthermore, ectopic overexpression of kinase-inactive MLK3 is able to rescue mitogen-induced activation of ERK in cells that have been depleted of endogenous MLK3, 15 and MLK3 missense mutations have been identified in gastrointestinal tumors that probably affect MLK3 scaffold properties but not its kinase activity. 25 In addition, MLK3 has been shown to limit RhoA activation by binding p63Rho guanine nucleotide exchange factor (GEF), independently of its catalytic activity. 26 Interestingly, p63RhoGEF has been identified as a key mediator of angiotensin II-dependent RhoA activation in VSMC. 27 RhoA is abundantly expressed in VSMC and controls a wide range of cellular functions, such as contraction, migration, and proliferation, 28, 29 and it is thought that many of the beneficial, nonlipid-lowering effects of statins used in the prevention and treatment of cardiovascular diseases are because of their ability to inhibit RhoA. 30 Furthermore, inhibition of the RhoA effector protein, Rho kinase (ROCK), inhibits intimal hyperplasia, [31] [32] [33] indicating that the Rho/ROCK pathway promotes neointima formation in response to injury.
The goal of this study was to determine the role of MLK3 in VSMC proliferation and neointima formation. We demonstrate that MLK3 limits RhoA activation and injury-induced neointima formation by binding to and inhibiting the activation of p63RhoGEF. In MLK3-deficient cells, activation of p63Rho-GEF proceeds in an unchecked manner, leading to a net increase in RhoA pathway activation. In addition, MLK3 catalytic activity is required for JNK activation, which, through reduction of MLK3-p63RhoGEF association, provides a feedback mechanism to dampen MLK3-mediated attenuation of RhoA pathway activation and cell proliferation. Together, these studies establish an important function for MLK3 in VSMC proliferation and intimal hyperplasia in response to vascular injury.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

MLK3 Deficiency Promotes Neointima Formation In Vivo
MLK3 is an MAP kinase kinase kinase that activates multiple MAPK pathways, 12 and MAPKs play a central role in the development of injury-induced neointimal hyperplasia. 34 Therefore, we anticipated that Mlk3 −/− mice would be protected against neointimal hyperplasia after endothelial denudation. Surprisingly, we found significant injury-induced neointimal hyperplasia and thickening of the vessel wall in MLK3 knockout (KO) mice compared with minimal neointima formation in injured wildtype (WT) mice ( Figure 1A ). Immunohistochemical staining of smooth muscle α-actin demonstrated that VSMC are the main cellular component in the injury-induced neointimal area in Mlk3 −/− mice ( Figure 1A , bottom). Morphometric analysis of uninjured and injured carotid arteries from 8 mice per genotype confirmed a significant neointimal area in Mlk3 −/− mice ( Figure 1B ). In addition, morphometric measurements revealed a significant increase in medial thickness in injured arteries of MLK3 KO compared with WT mice ( Figure 1C) . No difference in neointimal area and medial thickness was observed between uninjured control carotid arteries of WT and Mlk3 −/− mice ( Figure 1B and 1C) . Together, these data demonstrate that MLK3 deficiency promotes injury-induced neointima formation.
MLK3 Deficiency Increases VSMC Proliferation In Vitro
Previous studies have established that proliferation of VSMC is involved in neointimal hyperplasia, 35 and we found that VSMC are the main cellular component in the injury-induced neointimal area in MLK3 KO mice. Therefore, we isolated primary VSMC from WT and Mlk3 −/− mice to determine the mechanism by which MLK3 deficiency exacerbates neointima formation. On injury or when established in culture, VSMC undergo a switch from a contractile to a synthetic phenotype, which is associated with changes in morphology, cytoskeleton, and synthesis and secretion of extracellular matrix components. To analyze MLK3 smooth muscle cell phenotype, we isolated primary VSMC from WT and ]thymidine incorporation into DNA with maximal 6-fold increase observed at platelet-derived growth factor (PDGF)-BB concentrations of 10 ng/mL, in contrast to the 3-fold increase observed in WT cells ( Figure 2B ). Together, these data show that MLK3 deficiency increases the growth rate of VSMC in response to growth factors in vitro.
MLK3 Deficiency Increases RhoA Pathway Activation
The RhoA pathway has been established as an important mediator of VSMC proliferation, 28, 33 and previous studies have demonstrated that MLK3 expression attenuates RhoA activation. 17, 26 Therefore, to determine the underlying mechanism for increased proliferation of Mlk3 −/− VSMC, we next evaluated RhoA activation. Using a glutathione S-transferase (GST)-Rhotekin pulldown assay that specifically recognizes active, GTP-bound RhoA in combination with immunoblot analysis, we found that RhoA activation was significantly higher in MLK3-deficient compared with WT VSMC ( Figure 3A ). It has been well documented that activation of RhoA is associated with translocation to the membrane. Therefore, we performed subcellular fractionations to monitor the distribution of RhoA by immunoblot analysis. We observed that RhoA translocation to the membrane was increased in MLK3 KO VSMC compared with WT VSMC ( Figure 3B ). Because many vascular functions of RhoA are mediated by the RhoA effector protein, ROCK, we next analyzed ROCK activation. Using phosphorylation of the ROCK target protein MYPT1 (myosin phosphatase target subunit 1) as marker, we found that activation of ROCK is increased in Mlk3 −/− VSMC compared with WT cells ( Figure 3C ). Together, these data suggest that MLK3 deficiency increases the activation of RhoA and ROCK in VSMC, which may result in increased VSMC proliferation. To test this, we treated VSMC with Y27632, an inhibitor that specifically inhibits ROCK activity and has been demonstrated to inhibit VSMC proliferation in vitro and injury-induced neointima formation in vivo, 36 and analyzed the growth rate of WT and MLK3-deficient VSMC in medium supplemented with 10% fetal bovine serum. Treatment with the ROCK inhibitor significantly reduced growth of WT and MLK3 KO VSMC ( Figure 3D ), placing MLK3 upstream of RhoA and ROCK.
One downstream effect of RhoA activation is to reduce the expression of cell cycle inhibitors such as the cyclin-dependent kinase inhibitors p21
Waf1/Cip1 and p27 Kip1 , 37 and numerous studies have implicated p27
Kip1 and p21 Cip1 in the control of VSMC proliferation and neointima formation. [38] [39] [40] Therefore, we performed immunoblot analysis of p27
Kip1 and p21 Cip1 in WT and Mlk3 −/− VSMC. p27 Kip1 expression was decreased in MLK3-deficient compared with WT cells ( Figure 3E ). Similarly, in agreement with the increased proliferative capacity of MLK3-deficient VSMC, we observed significantly reduced p21
Cip1 levels in Mlk3 −/− VSMC ( Figure 3F ). Together, these data indicate that MLK3 deficiency results in increased activation of the Rho/ ROCK pathway and decreased p27
Kip1 and p21 Cip1 expression.
MLK3 Limits p63RhoGEF Activation
Rho GTPases are activated by GEFs that catalyze the exchange of GDP for GTP. Earlier studies have suggested that MLK3 modulates RhoA activity by binding to p63RhoGEF. 26 To evaluate the effect of MLK3 deficiency on p63RhoGEF activation, we used RhoA G17A affinity chromatography, in combination with immunoblot analysis of p63RhoGEF. This assay takes advantage of a nucleotide-free mutant RhoA, with a high affinity for active GEFs. 41 PDGF-BB treatment caused p63RhoGEF activation in cells of both genotypes; however, PDGF-induced (Figure 4A ), indicating that MLK3 expression suppresses p63RhoGEF activation. Next, we determined the effect of MLK3 expression on the ability of p63RhoGEF to regulate RhoA activity. For this, we coexpressed GST-tagged p63RhoGEF and WT MLK3 (MLK3 WT) or a kinase-inactive mutant (MLK3 KI) and analyzed RhoA-GTP loading as described above. Overexpression of p63Rho-GEF activated RhoA, which was inhibited by coexpression of both MLK3 WT and KI ( Figure 4B) . Together, these results show that MLK3 deficiency increases p63RhoGEF activation, and interaction of MLK3 with p63RhoGEF limits RhoA-GTP loading, independently of MLK3 catalytic activity.
Reconstitution of MLK3 Expression in MLK3-Deficient Cells Attenuates VSMC Proliferation
Based on our finding that MLK3 deficiency increases activation of the RhoA pathway and that interaction of MLK3 with p63RhoGEF limits RhoA activation, we hypothesized that reconstituting MLK3 expression in VSMC isolated from Mlk3 −/− mice will attenuate activation of the RhoA pathway and reduce cell proliferation. To test this, Mlk3 −/− VSMC were transduced with retrovirus expressing empty vector, MLK3 WT, or MLK3 KI, and proliferation was investigated. As expected, PDGF-induced DNA synthesis was significantly attenuated in cells reconstituted with MLK3 WT and KI compared with MLK3 KO VSMC expressing empty vector ( Figure 5A ). However, surprisingly, we observed that PDGF-BB treatment of MLK3-deficient VSMC reconstituted with MLK3 WT caused a 2-fold increase in the [
3 H] thymidine incorporation into DNA, whereas PDGF-induced DNA synthesis was not significantly increased in cells reconstituted with catalytically inactive MLK3 ( Figure 5A) Figure 5B ). Together, these data indicate that MLK3 expression modulates RhoA activation but uncover an important role for MLK3 kinase activity in the regulation of VSMC proliferation.
MLK3 Mediates PDGF-Induced JNK Activation in VSMC
Because several MAPK pathways have been implicated in the development of injury-induced neointimal hyperplasia, 34 we assessed MAPK activation in WT and Mlk3 −/− VSMC to determine which subfamily of MAPKs mediates the effect of MLK3 on VSMC proliferation. Treatment of WT cells with PDGF-BB caused increased JNK activation that was detected by immunoblot analysis using an antibody to the JNK T-loop phosphorylation site. JNK phosphorylation was markedly reduced in MLK3-deficient cells, whereas loss of MLK3 had little effect on PDGFinduced phosphorylation of ERK ( Figure 6A ). These data suggest that MLK3 is not required for ERK activation but contributes to PDGF-induced JNK activation in VSMC. To test whether JNK activity is required for VSMC proliferation, we treated WT and MLK3-deficient cells with SP600125, a compound that specifically inhibits JNK activity, and analyzed the growth rate of WT and MLK3-deficient VSMC in medium supplemented with 10% fetal bovine serum. Treatment with the JNK inhibitor significantly reduced growth of WT but had only minimal effects in MLK3 KO VSMC (Figure 6B ), suggesting that MLK3-dependent activation of JNK contributes to VSMC proliferation. Previous studies have demonstrated that activation of JNK decreases binding of MLK3 to p63RhoGEF 26 and thus attenuates MLK3-mediated decrease of cell proliferation. Therefore, we hypothesized that JNK inhibition increases the interaction of MLK3 with p63Rho-GEF. To test this hypothesis, we coexpressed MLK3 and GSTtagged p63RhoGEF or GST control in the presence or absence of SP600125, affinity-purified proteins using glutathione sepharose, and determined MLK3 binding by immunoblot analysis using an antibody specific for MLK3. We found that MLK3 interacts with GST-p63RhoGEF but not with GST control (Figure 6C , left) and that this association is increased in the presence of the JNK inhibitor ( Figure 6C, right) .
Discussion
Previously, it was shown that MLK3 deficiency has either no effect or an inhibitory effect on cell proliferation. 15, 18 In contrast, here we find that MLK3-deficient VSMC display accelerated proliferation in response to growth factor and serum stimulation in vitro, resulting in neointimal hyperplasia after endothelial denudation, whereas no difference in neointimal area is observed in uninjured carotid arteries of WT and Mlk3 −/− mice. Comparison of carotid arteries of MLK3 KO and WT mice also reveals an increase in medial thickness in response to injury, but not in uninjured vessels.
The underlying mechanism for this is increased activation of the RhoA pathway. Genetic inactivation and pharmacological inhibition have established RhoA and ROCK as important mediators of VSMC proliferation, 28, 33, 36 and, in agreement with previous reports, 17, 26 we find increased RhoA and ROCK activation in MLK3-deficient VSMC. We show that treatment of cells with the ROCK inhibitor Y27632 significantly reduced the growth of WT and MLK3 KO VSMC in medium supplemented with 10% fetal bovine serum, placing Rho A and ROCK downstream of MLK3. However, we observe no difference in the phenotype of quiescent VSMC or growth of WT and Mlk3 −/− VSMC under basal conditions. Interestingly, earlier studies have demonstrated that although Rho activation is necessary for DNA synthesis, activation of this GTPase is not sufficient to induce proliferation in VSMC. 28 Instead, it seems to potentiate the effects of Ras/MAPK or growth factors to stimulate cell cycle progression. 37 One mechanism by which RhoA and ROCK activation controls VSMC proliferation is by modulating the expression of cell cycle inhibitors p21
Waf1/Cip1 and p27
Kip1
. 37, 42, 43 Consistent with this, we find decreased levels of p21
Waf1/Cip1 and p27 Kip1 in MLK3-deficient VSMC compared with WT cells.
Rho GTPases are regulated by Rho GEFs, which catalyze the conversion of Rho GTPases from the inactive GDP-bound to the active GTP-bound form. p63RhoGEF was originally identified as a 63-kDa Rho-GEF that specifically activates RhoA. 44 Several lines of evidence indicate that p63RhoGEF specifically binds to Gα q/11 , but not Gα 12/13 subunits of heterotrimeric G proteins, thereby linking Gα q/11 -coupled receptors to RhoA activation. [45] [46] [47] Here, we show, in agreement with previous studies, 26 that MLK3 associates with p63RhoGEF and inhibits p63RhoGEF-induced RhoA activation measured by GST-Rhotekin pulldown assay. Interestingly, p63RhoGEF was shown to be a key mediator of angiotensin II-dependent signaling processes in VSMC, 27 as well as serum-dependent RhoA activation and chemotactic migration in breast cancer cells. 48 Because migration of VSMC from the media to the intima is a mechanism that contributes to neointima formation, future studies will focus on the role of MLK3 in VSMC migration.
Our studies also show that PDGF-induced JNK activation is attenuated in MLK3-deficient cells compared with WT VSMC. This indicates a nonredundant role for MLK3 in PDGF-induced JNK activation in VSMC in contrast to the redundant function observed in mouse embryonic fibroblasts. 18 In addition, we do not find that MLK3 is required for ERK activation in VSMC, contrary to studies in tumor cells. 15 These differences may be caused by redundancy of MLK3 with other MLK isoforms in specific cell types.
We demonstrate that reconstitution of MLK3-deficient VSMC with catalytically inactive MLK3 decreases cell proliferation. Similarly, pharmacological inhibition of JNK attenuates proliferation of WT but not MLK3 KO cells, indicating that JNK signals through MLK3 to regulate VSMC proliferation. We find that JNK inhibition increases binding of MLK3 to p63RhoGEF, providing a mechanism by which MLK3 regulates VSMC proliferation. How JNK modulates association of MLK3 and p63RhoGEF is unclear. Feedback phosphorylation of MLK3 by JNK has been demonstrated to affect MLK3 localization, 49 suggesting a potential mechanism for regulation of MLK3-p63RhoGEF interaction.
In summary, we show that MLK3 deficiency increases VSMC proliferation and exacerbates injury-induced neointima formation because of increased p63RhoGEF, RhoA, and ROCK activation. Furthermore, we demonstrate that loss of JNK activation, because of the expression of catalytically inactive MLK3 or pharmacological inhibition of JNK, attenuates VSMC proliferation. Furthermore, we provide evidence that inhibition of JNK increases binding of MLK3 to p63RhoGEF. Based on these data, we propose the following model for MLK3 function in VSMC: MLK3 association with p63RhoGEF decreases p63RhoGEF, RhoA, and ROCK activation and reduces VSMC proliferation and neointimal hyperplasia. In MLK3-deficient cells, activation of p63RhoGEF proceeds in an unchecked manner, leading to a net increase in RhoA pathway activation. In addition, MLK3 catalytic activity is required for JNK activation, which, through reducing binding of MLK3 to p63RhoGEF, provides a feedback mechanism to dampen MLK3-mediated attenuation of RhoA pathway activation and cell proliferation. Loss of JNK activation, because of the expression of catalytically inactive MLK3 or pharmacological inhibition of JNK, allows unrestricted interaction of MLK3 and p63RhoGEF, thus limiting the availability of ) mice were treated with platelet-derived growth factor (PDGF)-BB for 10 minutes. p63Rho-GEF activation was determined by RhoA G17A affinity chromatography in combination with immunoblot analysis. B, Glutathione S-transferase (GST)-p63RhoGEF and MLK3 WT or a kinaseinactive mutant (MLK3 KI) was coexpressed in HEK293 (human embryonic kidney) cells, and RhoA activation was determined by binding to GST-Rhotekin and subsequent immunoblot analysis. AC indicates affinity chromatography; and WB, Western blot. p63RhoGEF for RhoA pathway activation, ultimately causing a net decrease in RhoA pathway activation and cell proliferation. (Figure 6D) . Together, these studies establish an important role for MLK3 in VSMC proliferation and neointimal hyperplasia in response to vascular injury. −/− mice were cultured in DMEM containing 10% fetal bovine serum in the presence of JNK inhibitor (20 μmol/L) or vehicle control, and viable cell number was determined by direct counting. Data represent ±SEM from triplicate assays from 3 independent experiments. *Significant difference from untreated cells of the same genotype at P<0.05. C, Glutathione S-transferase (GST), GST-p63Rho guanine nucleotide exchange factor (GEF), and MLK3 were coexpressed in HEK293 (human embryonic kidney) cells and treated with SP600125 (20 μmol/L) overnight. GST-p63RhoGEF or GST control was affinity purified using glutathione sepharose, and MLK3 binding was determined by immunoblot analysis for MLK3. D, Proposed model for role of MLK3 in VSMC proliferation. MLK3 limits RhoA activation by binding to and inhibiting activation of p63RhoGEF. In addition, MLK3 mediates JNK activation, which feeds back to attenuate interaction of MLK3 and p63RhoGEF and releases inhibition of RhoA/Rho kinase (ROCK) activation by MLK3. AP indicates affinity purified; ERK-P, phosphorylated extracellular signal-regulated kinase; JNK-P, phosphorylated cJun NH 2 -terminal kinase; ns, statistically not significant; and WB, Western blot.
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